aktivdepot
: Brokerages Anticipate HTBX to Post ($0.14) Earning
Posted by Darrell McKinsey on Mar 17th, 2019
Heat Biologics Inc (NASDAQ:HTBX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation. Brokers have set a 12 month consensus target price of $6.50 for the company and are predicting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 73 out of 255 based on the ratings given to its competitors.
Posted by ABMN Staff on Mar 17th, 2019 // No Comments
CVI Holdings LLC purchased a new position in shares of Heat Biologics Inc (NASDAQ:HTBX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,557,768 shares of the biopharmaceutical company’s stock, valued at approximately $1,527,000. Heat Biologics comprises 3.4% of CVI Holdings LLC’s portfolio, making the stock its 6th biggest position. CVI Holdings LLC owned about 6.70% of Heat Biologics at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also bought and sold shares of HTBX. Northern Trust Corp purchased a new position in shares of Heat Biologics during the second quarter valued at approximately $111,000. Vanguard Group Inc. lifted its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 136,256 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 136,256 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Heat Biologics during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 16.39% of the company’s stock.
Wie oft willst du noch fincanna aufführen? Ja ist in die Hose gegangen, so what?
Hier gehts um Heat, ganz andere Nummer. Bist doch selbst lt. deiner Aussage jetzt long. Kann wohl nich so übel sein... Immer diese erbärmliche Geblubbere hier von dir +gähn+
bestimmte Ereignisse als Prüfstein für Kursbewegungen zu sehen. Ist ja erstmal nur eine (weitere) Präsentation der bekannten Ergebnisse. Darüber hinaus allerdings ist es schon vielsagend, dass der Fokus von Heat offenbar in China liegt. Deshalb kann sich auch aus der morgigen Präsentation kurzfristig in der Folge natürlich etwas ergeben. Kann mir gut vorstellen, dass es mehrere Interessenten gibt, wie es das Unternehmen ja auch angibt.
Zeigen Sie den vorbörslichen Aktienkurs für Heat Biologics, Inc. (HTBX) auf NASDAQ.com an, die Quelle Ihres Vertrauens für Börsenneuigkeiten und Aktieninformationen.
....Jeff Wolf, Heat's CEO, commented, "We are making excellent progress advancing HS-110 and recently reported interim Phase 2 non-small cell lung cancer (NSCLC) data on HS-110 plus nivolumab at the ASCO-SITC Clinical Immuno-Oncology Symposium....
.....We believe we are the first company to present clinical data in advanced NSCLC with patients whose prior checkpoint inhibitor treatment has failed. The results have generated significant interest within the industry and oncology community."...
Thread abonnieren
